WASHINGTON (CBS News) — Pfizer said Wednesday that a final assessment of trial data on the COVID-19 vaccine it developed in conjunction with German company BioNTech showed it was 95% effective, and that it would apply for emergency use authorization with the U.S. Food and Drug Administration “within days.”
It was the latest hopeful news for a world desperate to turn the tide on the coronavirus pandemic that has killed more than 1.3 million people globally, and almost 250,000 in the U.S. alone.READ MORE: Youth Athletes Getting Ready For Outdoor Competition To Resume
In a statement released early Wednesday, Pfizer said the efficacy of its vaccine was consistent “across age, gender, race and ethnicity demographics,” and that trial data after two months had met the criteria laid out by the FDA to demonstrate both the safety and function of the vaccine.READ MORE: OC Receives More Than 83K COVID-19 Vaccine Doses In Single Day
“Pfizer and BioNTech plan to submit a request within days to the FDA for an EUA [Emergency Use Authorization] based on the totality of safety and efficacy data collected to date,” the U.S. pharmaceuticals giant said.
Pfizer became the first vaccine maker to claim an extremely high efficacy for its formula last week, saying preliminary data showed it to be more than 90% effective at preventing new coronavirus infections. Wednesday’s announcement cemented those results with final data, and made them even more optimistic by matching preliminary efficacy data reported by Moderna, another American vaccine maker that hopes to seek EUA in the U.S. soon.MORE NEWS: LA County Sheriff's Motorcycle Deputy Thomas Albanese Killed In Lakewood Crash